FDA approves 1st eye drop that sharpens near vision
Big news for anyone squinting at their phone: the FDA has approved Yuvezzi, the first-ever dual-action eye drop for presbyopia (that's age-related trouble focusing up close).
Made by Tenpoint Therapeutics, Yuvezzi is designed to sharpen your near vision without messing with your distance sight.
It's expected to hit US shelves in Q2 2026.
How does it work?
Yuvezzi combines two ingredients—carbachol and brimonidine tartrate.
Carbachol quickly tightens your pupils to help you see up close, and brimonidine keeps that effect going for up to 10 hours.
You only need one dose a day, so it fits easily into a routine.
In trials, the drops improved near vision for up to
In clinical trials with over 800 adults, Yuvezzi produced statistically significant near-vision improvements — including three-line or greater improvements lasting up to eight hours — without worsening distance vision.
No treatment-related serious adverse events were observed in the BRIO II safety dataset covering over 72,000 treatment days; common adverse reactions included headache, impaired or temporary visual impairment, and temporary eye pain or eye irritation.
Overall: promising results if you're tired of reading glasses.